Carmell to Host Investor Webinar, “Unveiling the Secretome: On the Eve of Product Launch” Featuring Key Opinion Leaders in the Medical Aesthetics Field
Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.
- Carmell's Secretome technology delivers 1000+ growth factors, proteins and peptides extracted from allogeneic human platelets in a twelve-month shelf-stable and biologically active formulation.
- Carmell’s technology was previously being developed as a BLA and has Phase 2 human clinical data supporting safety and efficacy.
- In comparison, other aesthetic products feature 1-2 synthetic proteins with sparse evidence of clinical efficacy.
- Carmell aims to launch a limited-edition product this month followed by 9 other skincare products over the summer 2024.